1. Home
  2. CINT vs ENTA Comparison

CINT vs ENTA Comparison

Compare CINT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CI&T Inc

CINT

CI&T Inc

HOLD

Current Price

$4.95

Market Cap

566.6M

Sector

Technology

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.85

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CINT
ENTA
Founded
1995
1995
Country
Brazil
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
566.6M
486.3M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
CINT
ENTA
Price
$4.95
$13.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$7.00
$20.40
AVG Volume (30 Days)
193.6K
207.3K
Earning Date
03-11-2026
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
46.10
N/A
EPS
0.27
N/A
Revenue
$467,906,000.00
$66,980,000.00
Revenue This Year
$13.00
$0.99
Revenue Next Year
$12.62
$0.19
P/E Ratio
$18.16
N/A
Revenue Growth
1.90
0.58
52 Week Low
$3.98
$4.09
52 Week High
$7.50
$17.15

Technical Indicators

Market Signals
Indicator
CINT
ENTA
Relative Strength Index (RSI) 52.95 54.63
Support Level $4.84 $13.18
Resistance Level $5.16 $15.55
Average True Range (ATR) 0.23 0.66
MACD -0.02 0.15
Stochastic Oscillator 24.53 48.55

Price Performance

Historical Comparison
CINT
ENTA

About CINT CI&T Inc

CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: